Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. - Wikidata - wikimedia - TriplyDB

Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.

Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.

http://www.wikidata.org/entity/Q40102250

about

Mouse models of liver cancer: Progress and recommendations The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.Melittin restores PTEN expression by down-regulating HDAC2 in human hepatocelluar carcinoma HepG2 cells.Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma.Recombinant VP1, an Akt inhibitor, suppresses progression of hepatocellular carcinoma by inducing apoptosis and modulation of CCL2 production Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIα degradation in hepatocellular carcinoma cells Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cells Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases.Estrogen represses hepatocellular carcinoma (HCC) growth via inhibiting alternative activation of tumor-associated macrophages (TAMs).Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma.Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination.A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.Targeting histone deacetylases for the treatment of disease Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42.Cervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis.Medical treatments: in association or alone, their role and their future perspectives: novel molecular-targeted therapy for hepatocellular carcinoma.The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.Emerging signaling pathways in hepatocellular carcinoma.Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma.The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease.An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA.Suppressive effect of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) on hepatitis C virus replication.Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.Oestrogen attenuates tumour progression in hepatocellular carcinoma.Novel cinnamyl hydroxyamides and 2-aminoanilides as histone deacetylase inhibitors: apoptotic induction and cytodifferentiation activity.AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit.An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine.A novel treatment strategy in hepatocellular carcinoma by down-regulation of histone deacetylase 1 expression using a shRNA lentiviral system.Characterization of the regulation and function of zinc-dependent histone deacetylases during rodent liver regeneration.Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses the pro-oncogenic effects induced by hepatitis B virus pre-S2 mutant oncoprotein and represents a potential chemopreventive agent in high-risk chronic HBV patients.Molecular expression analysis of beta-naphthoflavone-induced hepatocellular tumors in rats.Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: efficacy of tributyrin, a butyric acid prodrug.

P2860

Q26799788-33AB8D8E-2427-45A2-82AD-4935A8C81D8E Q28751751-93DFDF3E-8D14-46AD-AE0C-695771964602 Q30464276-80ABE04D-6D68-41D3-AE87-E52390F1DEDF Q33559887-2E1A1E5F-5370-43B2-926D-CBF73F30687E Q33785710-659FB255-4F5D-4539-A0D1-03D781E2F8DF Q33986185-29B77605-FC9E-448E-9CE5-AEF10D193C4A Q34088141-8CA18C61-F0B6-49FF-A666-26154104A2B3 Q34360164-4F7B7C60-BC5A-4770-8030-9CFB43353DDB Q34681633-8DE63AEB-3512-44B2-B6F4-E07B4660B0BE Q35968727-0FF88069-5F14-4469-A951-A1552D2EF361 Q36129967-817B0E59-3CBC-4E47-B821-3FDEE76235B8 Q36211604-C2DB6C32-2C99-40F4-B9F4-ADF331821887 Q36256343-F521D3D8-524F-400D-B5F1-4D41740C0ED4 Q36315855-98370EAE-E6E5-42E9-9BCA-77950FBFCE2B Q36418759-06F8C746-AEBA-4515-9395-C80F089D4F1D Q36758025-1A62643A-15F7-4783-8B2E-7728491E8B63 Q37198835-296E1A89-D8B6-466B-8B68-16141C254CF1 Q37200466-E5035B29-5562-4DC9-B16E-8CCE5C97DB96 Q37296159-D0751C70-21CF-428E-B1A1-FCB01A2B1F83 Q37447349-4AD9A00A-8115-46CA-B6E5-A1240B845D0E Q37579334-3090453F-10D0-4959-95E5-C88A793D1119 Q37639189-7E6AAB68-B097-4538-93B2-C53F42821FB8 Q37725434-BC942E3A-5C09-4352-948E-16A5A48E4716 Q38155507-963FE69D-FB88-4D95-A10A-EA4FDF11DF5E Q38290607-2C6A7670-7DC3-4A67-9CE9-BC95D3992A04 Q38717140-3B9D3944-84E2-4D25-91B4-AD870C49F7D3 Q39012545-10285791-4060-4A24-AD1A-288BB367A53D Q39150897-30B359A2-4DDC-4E6A-B889-01DE54D6F047 Q39177306-970B50E8-B85F-4B97-A689-6D7BE04D1622 Q39244903-271C0440-748D-4AB9-9FAA-F93F86E9B144 Q39388489-ECD32376-5488-4D45-9263-39F686CA8686 Q39581390-C899132D-16C2-4EAC-9CAA-E810E6AF094F Q39726849-F6C77A72-2A0F-4566-93E6-6E3EC2E70EBE Q39784264-C221C2E3-7FE3-4150-940E-8D71E9C75438 Q40832236-994449A5-07B2-4DE6-AE23-0C3DD6BC5724 Q42910308-30CBA9A5-9B2E-4747-87A3-491533B67EA1 Q45203862-72B50AA9-5C08-418F-BBC6-FE034AD41F65 Q46038783-035FC91E-7981-4215-8715-D3CFA0768B98 Q46132555-2907260D-B678-4830-A8D0-96106719A80E

P2860

Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.

http://www.wikidata.org/entity/Q40102250

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Efficacy of a novel histone de ...... s of hepatocellular carcinoma.

@en

type

label

Efficacy of a novel histone de ...... s of hepatocellular carcinoma.

@en

prefLabel

Efficacy of a novel histone de ...... s of hepatocellular carcinoma.

@en

P1433

Q40102250-C3277714-95CD-4CB7-BF0A-7B0DE4E3C41B

P1476

Q40102250-F0C48C0B-9A61-4DDB-9E9B-98A28DC27546

P2093

Q40102250-09102688-9531-497D-A3E7-E1ACECECCEB0

Q40102250-523CBEE6-354B-4418-8816-4AB9B2B4204C

Q40102250-5C995277-8B91-4F02-B98D-741D2DA614D9

Q40102250-706D731A-E9E4-4432-A652-ED3A4034CB17

Q40102250-AC61B147-D900-4E65-A591-41ECCD600D99

Q40102250-B3BDD65D-B1EC-4A17-B393-CDA4F0982916

Q40102250-B8229C57-34E9-4DF0-A5CC-90CD40BCEFE3

Q40102250-BFD66AB4-3228-43E3-9613-9D086309C437

Q40102250-D41D2623-631F-43A1-8085-449F05FDCC1D

P2860

Q40102250-7F495A80-337D-4D68-BE3C-6F2FE5AD853D

Q40102250-E3DBDA6A-E727-4487-8254-64504DE349D5

P304

Q40102250-2F69FAB8-305D-49FE-A828-4A50516650E3

P31

Q40102250-9F1B8AAE-C1BC-466E-9811-FE4F144DF586

P356

Q40102250-68944D00-017A-4B7D-932A-214392541CF7

P407

Q40102250-84ABD3BF-B5AC-44FD-8E5A-1F5160754896

P433

Q40102250-883A9FED-5B61-4EEA-9942-148D74E17810

P478

Q40102250-1EBCBA4D-3E8F-4ED3-89C2-19DE98408689

P50

Q40102250-29DBD46E-16E4-43A5-A7D8-216120E3D085

Q40102250-8D152175-A816-40BF-8B31-2E09993EB313

P577

Q40102250-D2E10E85-CFF0-4EE4-895D-710B54AE83C4

P5875

Q40102250-001EE494-8205-42DF-817C-28F41534E60D

P698

Q40102250-0C6BFA18-E791-41DF-A644-E26DA559097A

P356

P1433

P1476

Efficacy of a novel histone de ...... s of hepatocellular carcinoma.

@en

P2093

Ching-Shih Chen

http://www.w3.org/2001/XMLSchema#string

Dasheng Wang

http://www.w3.org/2001/XMLSchema#string

Monica Tang

http://www.w3.org/2001/XMLSchema#string

Samuel K Kulp

http://www.w3.org/2001/XMLSchema#string

Te-Jung Chen

http://www.w3.org/2001/XMLSchema#string

Yen-Shen Lu

http://www.w3.org/2001/XMLSchema#string

Yoko Kashida

http://www.w3.org/2001/XMLSchema#string

Yu-Chieh Wang

http://www.w3.org/2001/XMLSchema#string

Zhong-Zhe Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibitors of histone deacetylase as new anticancer agents.

Expression and significance of new inhibitor of apoptosis protein survivin in hepatocellular carcinoma.

P304

1119-1130

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.21804

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

Jui-Hsiang Hung

P577

2007-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6183521

http://www.w3.org/2001/XMLSchema#string

P698

17654699

http://www.w3.org/2001/XMLSchema#string